Facilitating precision therapy in Prostate Cancer…
https://doi.org/10.1172/JCI194949 Wael Y. Mansour & team discover ERG overexpression as a biomarker for identifying patients with prostate cancer who can benefit from PARPi-based radiosensitization, enhancing radiotherapy efficacy and reducing toxicity. The image: Samples of an ERG-positive PCa tumor following irradiation and PARP inhibition reveal a bystander effect; p53-binding protein 1 foci (red) in ERG-positive (green) and ERG-negative cells; nuclei (blue).
1Department of Radiotherapy and Radiooncology and.
2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
3Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.